Cell line · CVCL_1269
Papers42
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 42
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Overcoming platinum resistance by the disulfiram metabolite CuET in novel preclinical models of human carcinomas. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Persistent TOP1 cleavage complexes in drug-tolerant cells drive adaptive resistance to EGFR-targeted therapies in lung cancer. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibition enhances the antitumor activity of HER3-DXd in non-small cell lung cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MiR-23c Regulates the Resistance to Gefitinib in EGFR Mutant Non-Small-Cell Lung Cancer Cells. | Cells | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Early-stage multi-cancer detection through a plasma extracellular vesicle protein signature. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CDK12/13 Drives Mitotic Arrest to Overcome Resistance to KRASG12C Inhibitors. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| SERPINB3 enhances NPM1 sumoylation via inhibiting SENP3's activity and promotes lung tumorigenesis. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Primate retroelement exonization and sexually dimorphic IL13RA1 transcription tune type 2 immune responses. | Sci Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Redundancy of the OST catalytic subunit facilitates therapeutic targeting of N-glycosylation. | Cell Chem Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Retroelement co-option disrupts the cancer transcriptional programme. | Genome Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. | Mol Cell | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PKN2 Is a Dependency of the Mesenchymal-like Cancer Cell State. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PubMed 39677793 | bioRxiv | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Biased signaling by mutant EGFR underlies dependence on PKCα in lung adenocarcinoma. | Cell Rep | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Potential Utility of a 4th-Generation EGFR-TKI and Exploration of Resistance Mechanisms-An In Vitro Study. | Biomedicines | 2024 | Cellosaurus cites it | PubMed | |
| PubMed 37994369 | bioRxiv | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of a lower potency target drives the anticancer activity of a clinical p38 inhibitor. | Cell Chem Biol | 2023 | Its Methods give the RRID and name the line | PubMed | |
| PUF60 promotes cell cycle and lung cancer progression by regulating alternative splicing of CDC25C. | Cell Rep | 2023 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1269/papers